Edition:
United States

Michele Gershberg

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

Dec 29 2013

After troubled rollout, Obamacare's new test starts on New Year's Day

New Year's Day will bring a fresh test for President Barack Obama's healthcare overhaul, as hundreds of thousands of Americans will begin to use the program's new medical coverage for the first time.

Dec 29 2013

After troubled rollout, Obamacare's new test starts on New Year's Day

New Year's Day will bring a fresh test for President Barack Obama's healthcare overhaul, as hundreds of thousands of Americans will begin to use the program's new medical coverage for the first time.

Dec 29 2013

After troubled rollout, Obamacare's new test starts on New Year's Day

Dec 29 New Year's Day will bring a fresh test for President Barack Obama's healthcare overhaul, as hundreds of thousands of Americans will begin to use the program's new medical coverage for the first time.

Aug 24 2012

Lilly drug slows Alzheimer's in some, fails main goals

NEW YORK/CHICAGO Eli Lilly and Co said its experimental Alzheimer's drug showed signs of slowing mental decline in patients with a mild form of the disease, even though it failed to meet the main goals of two large clinical trials, suggesting the treatment could be salvaged.

Jun 30 2012

Bristol-Myers to buy Amylin for about $5.3 billion

NEW YORK Bristol-Myers Squibb Co will buy biotechnology company Amylin Pharmaceuticals Inc for about $5.3 billion (3.37 billion pounds) in cash, helping Bristol-Myers extend its portfolio of diabetes treatments with the addition of drugs Byetta and Bydureon.

Jun 30 2012

Bristol-Myers to buy Amylin for about $5.3 bln

NEW YORK Bristol-Myers Squibb Co will buy biotechnology company Amylin Pharmaceuticals Inc for about $5.3 billion in cash, helping Bristol-Myers extend its portfolio of diabetes treatments with the addition of drugs Byetta and Bydureon.

Jun 29 2012

Bristol-Myers to buy Amylin for about $5.3 billion

NEW YORK Bristol-Myers Squibb Co will buy biotechnology company Amylin Pharmaceuticals Inc for about $5.3 billion in cash, helping Bristol-Myers extend its portfolio of diabetes treatments with the addition of drugs Byetta and Bydureon.

Feb 21 2012

Johnson & Johnson CEO Weldon to step down in April

NEW YORK Johnson & Johnson Chief Executive William Weldon will step down from his post in April after a series of recalls called into question the quality of the healthcare giant's products, from artificial hips to infant Tylenol.

Feb 21 2012

Johnson & Johnson CEO Weldon to step down in April

NEW YORK Johnson & Johnson Chief Executive William Weldon will step down from his post in April after a series of recalls called into question the quality of the healthcare giant's products, from artificial hips to infant Tylenol.

Feb 21 2012

Johnson & Johnson CEO Weldon to step down in April

NEW YORK Johnson & Johnson Chief Executive William Weldon will step down from his post in April after a series of recalls called into question the quality of the healthcare giant's products, from artificial hips to infant Tylenol.

Markets

  • U.S.
  • Europe
  • Asia
  • Sectors

Sector Summary